Search

Bremelanotide

[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

Hydroxyethyl ethylcellulose

Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

Ferrous cysteine glycinate

Nirsevimab

[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

Tiratricol

[A274073] Tiratricol is currently being investigated in US clinical trials. … Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).

Lumasiran

[L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394]

Glycyrrhizic acid

[T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis. … [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]

Tetradecyl hydrogen sulfate (ester)

Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids … Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report of injecting a 1% solution into spider angiomas in 144 patients was made.

Tofacitinib

Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.

Tozinameran

[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … FDA on July 13, 2020.